Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple SclerosisAcross non-active progressive MS (primary progressive and secondary ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple ...
As the Democratic Republic of Congo faces its 16th Ebola outbreak, aid cuts mean support for its response is dwindling, ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the ...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year ...
New infections drop 44 percent | The Herald (Top Stories) Raymond Jaravaza, [email protected] THE number of people living with HIV in Bulawayo has declined from 79 711 in 2020 to 76 608 in 2024, ...
Pharmaceutical Technology on MSN
FDA delays approval decision for Sanofi’s MS treatment tolebrutinib
A new FDA target action date of 28 December could bring tolebrutinib’s tumultuous development period to an end.
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 ...
We are delighted to present the inaugural Frontiers in Neurology "Women in Multiple Sclerosis and Neuroimmunology" series of ...
People with advanced, incurable or rare cancers fear dying before gaining access to targeted treatments as a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback